According to the agreement, Insilico Medicine will utilize its proprietary Pharma.AI platform to focus on the design and optimization of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialization procedures. The total contract value approaches $120 million, including development and commercialization milestone payments, as well as single-digit royalties based on net sales.

Topological defects govern how many advanced materials behave, but predicting them has traditionally required slow, resource-intensive simulations. Researchers at Chungnam National University have developed a deep learning method that predicts stable defect configurations in nematic liquid crystals in milliseconds rather than hours. This rapid and accurate approach could speed the design of advanced materials that currently rely on lengthy trial-and-error processes.